Sarah Foster 11/10/26 Sarah Foster 11/10/26 Pathos AI has announced strategic collaborations with Bristol Myers Squibb and Tempus AI Read More Sarah Foster 10/29/26 Sarah Foster 10/29/26 Alnylam Shares Commercial Growth and Pipeline Progress Read More Sarah Foster 10/29/26 Sarah Foster 10/29/26 Sironax Named to Fierce Biotech’s 2026 Fierce 15 List of Most Innovative Private Biotechs Read More Sarah Foster 10/28/26 Sarah Foster 10/28/26 Dewpoint Therapeutics Shares DPTX3230 Research Progress in ALS Read More Sarah Foster 10/23/26 Sarah Foster 10/23/26 Tempus Expands Collaboration with Moderna and Merck to Support Individualized Cancer Therapy Delivery Read More Sarah Foster 10/22/26 Sarah Foster 10/22/26 argenx Reports Commercial Growth and Phase 3 Progress Read More Sarah Foster 10/15/26 Sarah Foster 10/15/26 Pathos CEO Iker Huerga Shares How AI Can Move Promising Science Closer to Patients Read More Sarah Foster 10/5/26 Sarah Foster 10/5/26 CSL and Alentis Announce Global Partnership to Develop and Commercialize Lixudebart for Rare Kidney and Liver Diseases Read More Sarah Foster 10/2/26 Sarah Foster 10/2/26 Travere to Present Nine New Data Presentations at ASN Kidney Week 2026 Read More Sarah Foster 10/1/26 Sarah Foster 10/1/26 Evommune Presents Late-Breaking Phase 2a Data for EVO301 in Atopic Dermatitis at EADV 2026 Read More Sarah Foster 9/29/26 Sarah Foster 9/29/26 argenx Presents New VYVGART Data at AANEM and MGFA, Showing Earlier and Sustained Treatment Outcomes in MG and CIDP Read More Sarah Foster 9/28/26 Sarah Foster 9/28/26 Dewpoint Therapeutics' Ann Boija Delivers Featured Presentation at Discovery on Target 2026 Read More Sarah Foster 9/21/26 Sarah Foster 9/21/26 Travere Therapeutics Announces CEO Transition, Recognizing Eric Dube's Eight Years of Leadership Read More Sarah Foster 8/18/26 Sarah Foster 8/18/26 CSL Reports FY2026 Results, with Strong Cash Flow and Cost Savings Ahead of Target Read More Sarah Foster 8/17/26 Sarah Foster 8/17/26 Leal Therapeutics Closes $30 Million Series A Extension and Launches Schizophrenia Trial Read More Sarah Foster 8/11/26 Sarah Foster 8/11/26 Neurogene Reports Positive Long-Term Data for NGN-401 Gene Therapy in Rett Syndrome Read More Sarah Foster 8/4/26 Sarah Foster 8/4/26 Pathos AI Expands Its Oncology Pipeline with Alphamab, AstraZeneca and DeuterOncology Agreements Read More Sarah Foster 7/27/26 Sarah Foster 7/27/26 argenx to Acquire Forte Biosciences, Expanding Its Immunology Pipeline Read More Sarah Foster 7/23/26 Sarah Foster 7/23/26 argenx Delivers 60% Year-over-Year Growth in a Strong First Half of 2026 Read More Sarah Foster 7/22/26 Sarah Foster 7/22/26 Formation Bio Appoints Michael Ehlers as Chief Scientific Officer and Head of Research Read More Older Posts
Sarah Foster 11/10/26 Sarah Foster 11/10/26 Pathos AI has announced strategic collaborations with Bristol Myers Squibb and Tempus AI Read More
Sarah Foster 10/29/26 Sarah Foster 10/29/26 Alnylam Shares Commercial Growth and Pipeline Progress Read More
Sarah Foster 10/29/26 Sarah Foster 10/29/26 Sironax Named to Fierce Biotech’s 2026 Fierce 15 List of Most Innovative Private Biotechs Read More
Sarah Foster 10/28/26 Sarah Foster 10/28/26 Dewpoint Therapeutics Shares DPTX3230 Research Progress in ALS Read More
Sarah Foster 10/23/26 Sarah Foster 10/23/26 Tempus Expands Collaboration with Moderna and Merck to Support Individualized Cancer Therapy Delivery Read More
Sarah Foster 10/22/26 Sarah Foster 10/22/26 argenx Reports Commercial Growth and Phase 3 Progress Read More
Sarah Foster 10/15/26 Sarah Foster 10/15/26 Pathos CEO Iker Huerga Shares How AI Can Move Promising Science Closer to Patients Read More
Sarah Foster 10/5/26 Sarah Foster 10/5/26 CSL and Alentis Announce Global Partnership to Develop and Commercialize Lixudebart for Rare Kidney and Liver Diseases Read More
Sarah Foster 10/2/26 Sarah Foster 10/2/26 Travere to Present Nine New Data Presentations at ASN Kidney Week 2026 Read More
Sarah Foster 10/1/26 Sarah Foster 10/1/26 Evommune Presents Late-Breaking Phase 2a Data for EVO301 in Atopic Dermatitis at EADV 2026 Read More
Sarah Foster 9/29/26 Sarah Foster 9/29/26 argenx Presents New VYVGART Data at AANEM and MGFA, Showing Earlier and Sustained Treatment Outcomes in MG and CIDP Read More
Sarah Foster 9/28/26 Sarah Foster 9/28/26 Dewpoint Therapeutics' Ann Boija Delivers Featured Presentation at Discovery on Target 2026 Read More
Sarah Foster 9/21/26 Sarah Foster 9/21/26 Travere Therapeutics Announces CEO Transition, Recognizing Eric Dube's Eight Years of Leadership Read More
Sarah Foster 8/18/26 Sarah Foster 8/18/26 CSL Reports FY2026 Results, with Strong Cash Flow and Cost Savings Ahead of Target Read More
Sarah Foster 8/17/26 Sarah Foster 8/17/26 Leal Therapeutics Closes $30 Million Series A Extension and Launches Schizophrenia Trial Read More
Sarah Foster 8/11/26 Sarah Foster 8/11/26 Neurogene Reports Positive Long-Term Data for NGN-401 Gene Therapy in Rett Syndrome Read More
Sarah Foster 8/4/26 Sarah Foster 8/4/26 Pathos AI Expands Its Oncology Pipeline with Alphamab, AstraZeneca and DeuterOncology Agreements Read More
Sarah Foster 7/27/26 Sarah Foster 7/27/26 argenx to Acquire Forte Biosciences, Expanding Its Immunology Pipeline Read More
Sarah Foster 7/23/26 Sarah Foster 7/23/26 argenx Delivers 60% Year-over-Year Growth in a Strong First Half of 2026 Read More
Sarah Foster 7/22/26 Sarah Foster 7/22/26 Formation Bio Appoints Michael Ehlers as Chief Scientific Officer and Head of Research Read More
